About this trial
This study aims to evaluate the effect of L-arginine supplementation on cognitive function in geriatric patients. Eligible participants will receive either L-arginine (6 grams once daily) or placebo, and their cognitive performance will be assessed using validated cognitive assessment tools over the study period. The participants will receive the intervention for 4 weeks and followed up every 2 weeks. The primary outcome is improvement in cognitive function, while secondary outcomes include safety, tolerability, and quality of life measures. The findings may provide evidence for the potential role of L-arginine in supporting cognitive health in elderly populations.
Eligibility criteria
Qualifiers
Age >60 years
Montreal Cognitive Assessment (MoCA) test score from 10-25 (mild to moderate cognitive impairment)
Disqualifiers
Presence of neurodegenerative diseases (e.g.: Alzheimer's disease, Parkinson's disease, Huntington's disease, Multiple Sclerosis)
Patients with history of L-arginine intolerance or allergy
Patients with asthma
Patients who recently had an acute myocardial infarction
Trial design
Treatments tested in this trial
- L-Arginine
- Placebo